Phaseline

Targets › NR1H4

NR1H4 (Bile acid receptor): drug programs, companies and trials

11 programs from 11 companies in 12 trials: 7 Phase 2, 3 Phase 4, 2 Phase 3; Gastroenterology, Oncology, Immunology; next expected readout Dec 2026.

Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). (UniProt, Q96RI1)

Open in Phaseline: the race on NR1H4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Yongquan ShiUrsodiol
Bile acid receptor FXR agonist
NR1H4Phase 4Gastric Intestinal Metaplasia–
Ain Shams UniversityUrsodiol
Bile acid receptor FXR agonist
NR1H4Phase 4Non Alcoholic Fatty Liver Diseases (NAFLD)–
Peking Union Medical College HospitalUrsodiol
Bile acid receptor FXR agonist
NR1H4Phase 4Primary Biliary Cholangitis–
Hospital General Universitario de AlicanteUrsodiol
Bile acid receptor FXR agonist
NR1H4Phase 3Acute Pancreatitis Due to GallstonesJul 2027
Xijing Hospital of Digestive DiseasesUrsodiol
Bile acid receptor FXR agonist
NR1H4Phase 3Primary Biliary Cholangitis (PBC)Dec 2035
Jinling Hospital, ChinaUrsodiol
Bile acid receptor FXR agonist
NR1H4Phase 2Kidney CancerDec 2026
Tanta UniversityObeticholic Acid
Bile acid receptor FXR agonist
NR1H4Phase 2Non-alcoholic SteatohepatitisDec 2026
Eli LillyLY4395089
Farnesoid X receptor (FXR) agonist
NR1H4Phase 2Colitis, Ulcerative; Crohn DiseaseJun 2027
National Cancer Institute (NCI)Obeticholic Acid
Bile acid receptor FXR agonist
NR1H4Phase 2Barrett EsophagusSep 2027
University Hospital, MontpellierUrsodiol
Bile acid receptor FXR agonist
NR1H4Phase 2Immune-Mediated CholestasisJan 2028
Gilead SciencesCilofexor
Bile acid receptor FXR agonist
NR1H4Phase 2Primary Biliary CholangitisDec 2028

Conditions

Primary Biliary Cholangitis (2) Immune-Mediated Cholestasis (1) Acute Pancreatitis Due to Gallstones (1) Colitis, Ulcerative (1) Crohn Disease (1) Gastric Intestinal Metaplasia (1) Non Alcoholic Fatty Liver Diseases (NAFLD) (1) Non-alcoholic Steatohepatitis (1) Kidney Cancer (1) Primary Biliary Cholangitis (PBC) (1) Barrett Esophagus (1)

Modalities

small molecule (9), mixed (1), protein or peptide (1)

Companies

University Hospital, Montpellier (1) Hospital General Universitario de Alicante (1) Gilead Sciences (1) Eli Lilly (1) Yongquan Shi (1) Ain Shams University (1) Peking Union Medical College Hospital (1) Tanta University (1) Jinling Hospital, China (1) Xijing Hospital of Digestive Diseases (1) National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.